T 0421/14 of 03.09.2019
- European Case Law Identifier
- ECLI:EP:BA:2019:T042114.20190903
- Date of decision
- 3 September 2019
- Case number
- T 0421/14
- Petition for review of
- -
- Application number
- 05732613.4
- IPC class
- A61K 31/44
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
- Applicant name
- Acorda Therapeutics, Inc.
- Opponent name
- Synthon B.V.
neuraxpharm Arzneimittel GmbH - Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2) (2007)European Patent Convention Art 54 (2007)European Patent Convention Art 56 (2007)European Patent Convention Art 83 (2007)Rules of procedure of the Boards of Appeal Art 12(4) (2012)
- Keywords
- Sufficiency of disclosure - after amendment
Amendments - added subject-matter (no)
Evidence submitted with the statement of grounds of appeal
Evidence - inadmissible (no)
Novelty - (yes)
Inventive step - (yes) - Catchword
- -
- Citing cases
- T 0542/23
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent with the following claims and a description to be adapted thereto:
claims 1 to 7 of auxiliary request 1 filed with the reply to the statements setting out the grounds of appeal, dated 16 September 2014